Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA

March 26, 2024 By The ASCO Post Staff

Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy have a particularly poor prognosis. These data suggest treatments should be individualized by stratifying risk, and front-line clinical trials of ovarian cancer should use MRD as a surrogate endpoint.

Related Content